**Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells**

Bryan D Shelby1,3, Heather L LaMarca1,3, Harris E McFerrin1,3, Anne B Nelson1, Joseph A Lasky2, Gang Sun4, Leslie Myatt4, Margaret K Offermann5, Cindy A Morris1,3 and Deborah E Sullivan*1,3

**Abstract**

**Background:** Kaposi's sarcoma associated herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), a highly vascularized neoplasm characterized by endothelial-derived spindle-shaped tumor cells. KSHV-infected microvascular endothelial cells demonstrate increased cyclooxygenase-2 (COX-2) expression and KS lesions have high levels of prostaglandin E2 (PGE2), a short-lived eicosanoid dependent on cyclooxygenase activity that has been linked to pathogenesis of other neoplasias. To determine whether increased COX-2 expression and PGE2 production is mediated by the angiogenic and tumorigenic KSHV-encoded G-protein coupled receptor (vGPCR), we developed a recombinant retrovirus to express vGPCR in Human Umbilical Vascular Endothelial Cells (HUVEC).

**Results:** In the present study, we show that vGPCR-expressing HUVEC exhibit a spindle-like morphology that is characteristic of KS endothelial cells and demonstrate selective induction of PGE2 and COX-2. By treating vGPCR-expressing HUVEC with selective and non-selective COX inhibitors, we show that vGPCR-induced PGE2 production is dependent on the expression of COX-2 but not COX-1.

**Conclusion:** Taken together, these results demonstrate that vGPCR induces expression of COX-2 and PGE2 that may mediate the paracrine effects of this key viral protein in KS pathogenesis.

**Background**

Kaposi's Sarcoma (KS) is a multi-cellular, highly vascularized neoplasm that is primarily composed of lymphoid, epithelial, and endothelial cells. The appearance of spindle-shaped cells, believed to be of endothelial origin, is a hallmark of KS lesions [1]. Kaposi's sarcoma associated...
herpesvirus (KSHV), also known as Human herpesvirus-8 (HHV-8), is the etiologic agent of both KS [2] and primary effusion lymphoma (PEL) [3] and is associated with multicentric castleman's disease (MCD) [4]. In KS, KSHV is found in spindle cells at all stages of the disease [1]. Changes in endothelial gene expression resulting from KSHV encoded gene products could provide insights into pathogenesis of KS.

KSHV has two distinct replication cycles, lytic and latent. During the lytic replication phase, infected cells express nearly all KSHV genes, including those genes required for viral DNA replication, virus packaging, and host immune response modulation to produce new virus. Latent KSHV replication is characterized by the expression of a small subset of KSHV genes that maintain infection and mediate evasion from host immune detection. Unlike lyric phase replication, viral DNA replication during latent phase is coupled to host cell replication and the latently infected cell does not produce new virus [5]. Most KSHV infected cells within KS lesions (>85%) persist in a latent state of replication [6,7].

The KSHV G-protein-coupled receptor (vGPCR) is a constitutively active lytic phase protein with significant homology to the human interleukin-8 (IL-8) receptor and has angiogenic and tumorigenic properties [8,9]. Transfection of vGPCR into endothelial and epithelial cells activates multiple transcription factors and signaling molecules including nuclear factor kappa B (NF-κB), extracellular signal regulated kinase 1/2 (ERK 1/2), p38 mitogen activated protein kinase (p38), nuclear factor of activated T cells (NFAT), c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), and protein kinase C/activator protein-1 (PKC/AP-1), all of which regulate COX-2 expression [8,10-15]. The KSHV vGPCR also induces the expression of paracrine factors [8,12].

Previous studies indicate that KS lesions have increased prostaglandin E2 (PGE2) production [16] and KSHV-infected human adult dermal microvascular endothelial cells have increased cyclooxygenase-2 (COX-2) expression [17,18]. COX-2 catalyzes the conversion of arachidonic acid to Prostaglandin H2 (PGH2), a precursor for prostaglandins including PGE2 that are synthesized by cell-type specific prostaglandin synthases [19-21]. Human umbilical vascular endothelial cells (HUVEC) express the two COX isoforms, COX-1 and COX-2, where COX-1 is ubiquitously expressed and COX-2 expression can be induced by inflammatory agents such as lipopolysaccharide (LPS) [22], and Interleukin-1β (IL-1β) [23], as well as mitogenic stimuli [24]. The mechanisms by which KSHV modulates expression of COX-2 and PGE2 in endothelial cells have yet to be associated with specific KSHV gene products.

Since vGPCR induces transcription factors known to activate COX-2 expression, we tested the hypothesis that COX-2 may be a downstream target of vGPCR intracellular signaling. Here, we demonstrate that vGPCR induces synthesis of COX-2 in HUVEC that in turn leads to PGE2 expression that may participate in KS pathogenesis. To our knowledge, the experiments described within this report provide the first association between a specific KSHV protein and COX-2-mediated prostaglandin production in endothelial cells.

**Results**

**vGPCR induces a morphological change in primary endothelial cells**

To stably express the KSHV vGPCR in primary HUVEC, cells were infected with a moloney murine leukemia virus-based BABE recombinant retrovirus (BABE-vGPCR) expressing vGPCR upstream of the coding sequence for green fluorescent protein (GFP) so that the bicistronic transcript mRNA should lead to the dual expression of vGPCR and GFP (Figure 1). At 72 hours post-infection, BABE-vGPCR-infected HUVEC exhibited a spindle cell-like morphology that mimicked the endothelial-derived KS spindle cells that populate KS lesions consistent with previous reports [12,25] (Fig. 2). Conversely, infection of HUVEC with the control retrovirus, BABE, failed to induce a spindle cell-like morphology; rather, these cultures maintained a cobblestone-like appearance, which is consistent with the morphology of uninfected HUVEC. The infection efficiency for both control and vGPCR-expressing viruses was approximately 60%, as determined by quantifying GFP-positive cells using fluorescence microscopy.

**vGPCR induces expression of COX-2 but not COX-1 in primary endothelial cells**

Most cell types, including HUVEC, express two COX isoforms, COX-1 and COX-2, which perform the same function of converting arachidonic acid to PGH2. Sharma-Wailia et al recently demonstrated that KSHV infection of human adult dermal microvascular endothelial (HMVEC-d) cells and human foreskin fibroblasts (HFF) induced the expression of COX-2 but not COX-1 [17]. To determine whether vGPCR, alone, may regulate the expression of COX isoform expression, protein lysates of BABE or BABE-vGPCR-infected HUVEC were analyzed for COX-1 and COX-2 expression by western blot at 24-hour intervals post-infection. HUVEC infected with BABE-vGPCR displayed a time-dependent increase in COX-2 expression that began at 24 hours post-infection and remained elevated through 72 hours (Fig. 3). COX-2 expression in BABE-infected-HUVEC was identical to that in uninfected HUVEC at each time point, providing evidence that the COX-2 expression in BABE-infected-HUVEC cultures does not reflect a reduction in COX-2 expression by the retrovi-
Figure 1
Schematic for the retroviral expression vector. The KSHV vGPCR is expressed as part of a bicistronic RNA upstream of an internal ribosomal entry site (IRES)-regulated GFP reporter cassette in the BABE retroviral plasmid [34]. The proviral segment of the BABE retroviral plasmid contains long terminal repeats (LTRs) that participate in proviral replication, an encapsidation sequence (ψ), and a selectable puromycin marker. This diagram is not drawn to scale.

**vGPCR induces COX-2 transcription**
Since COX-2 expression is transcriptionally regulated in most cases, we asked whether vGPCR activated COX-2 transcription. To assess vGPCR-mediated COX-2 promoter activity, a vGPCR expression vector (pcDNA3-vGPCR) was co-transfected along with a human COX-2 promoter-luciferase construct into HeLa cells. Expression of vGPCR transactivated the COX-2 promoter in a dose-dependent manner, leading to increased luciferase activity that was 4, 5, or 6 times greater than that from cells cotransfected with the COX-2 promoter luciferase construct and pcDNA3 lacking vGPCR (Fig. 4A). The pcDNA3 vector alone displayed minimal COX-2 promoter activity at each amount analyzed in these experiments. Activation of the cellular promoter should lead to increased mRNA synthesis and this was the case. Total RNA isolated from BABE and BABE-vGPCR transduced HUVEC were analyzed by quantitative real-time RT-PCR using COX-2 specific primers. As expected, COX-2 mRNA levels in vGPCR-expressing HUVEC were 3.2 and 4-fold higher than BABE-infected HUVEC at 16 and 24 hours post infection, respectively (Fig. 4B). Collectively, these results suggest that KSHV vGPCR induces COX-2 transcription through the activation of the COX-2 promoter.

**vGPCR-expression leads to increased PGE2 synthesis**
PGE2 synthesis is downstream of the cyclooxygenase conversion of arachidonic acid to PGH2. To determine whether the vGPCR-induced increase in COX-2 led to an increase in PGE2 synthesis, conditioned medium from BABE and BABE-vGPCR-transduced HUVEC was assayed to directly quantify secreted PGE2 (Fig. 5A). At 24 hours post-infection, PGE2 production from BABE-vGPCR-transduced HUVEC was two times greater than that from BABE-tranduced (control) HUVEC. PGE2 secretion from BABE-vGPCR-transduced HUVEC increased to over 20 times greater at 48 hours post-infection with the concentration of PGE2 exceeding 1.5 ng/ml in conditioned medium from BABE-vGPCR-transduced HUVEC. The uninfected HUVEC used in these experiments secreted low levels of PGE2 (50 pg/ml or less per culture) and infection with BABE did not increase PGE2 secretion above that detected from uninfected HUVEC (data not shown). Thus, KSHV vGPCR significantly increased PGE2 secretion in a time-dependent manner when expressed in primary HUVEC and, since vGPCR induces COX-2 but not COX-1 expression (Fig. 2), the increased PGE2 secretion was likely to result from increased COX-2 expression.

**vGPCR-induced PGE2 secretion requires COX-2**
To confirm the role of COX-2 in vGPCR-induced PGE2 secretion, SC-560 (COX-1 selective inhibitor), NS-398 (COX-2 selective inhibitor), or Indomethacin (Non-selective COX inhibitor) was added to vGPCR-expressing HUVEC at 24 hours post-infection for a 24-hour treatment. The concentrations of each COX inhibitor used were based upon the published IC50 values: SC-560 (COX-1, 9 nM; COX-2, 6 μM), NS-398 (COX-1, 100 μM; COX-2, 0.1 μM), and Indomethacin (COX-1, 2 μM; COX-2, 20 μM) [26-28]. BABE-vGPCR-transduced HUVEC treated with either NS-398 or with indomethacin demonstrated a dose-dependent decrease in PGE2 secretion. In contrast, treatment with the selective COX-1 inhibitor SC-560 had no significant effect on PGE2 secretion of vGPCR-expressing HUVEC (Fig. 5B). These results demonstrate that the increased production of PGE2 in vGPCR-expressing HUVEC is dependent on vGPCR-induced COX-2 activity.

**Discussion**
KS lesions are multi-cellular, highly vascularized neoplasms that express high levels of growth and inflammatory factors. There is increasing evidence that vGPCR plays a key role in KS development but the mechanisms involved are not fully understood. Aberrant induction of COX-2 and up-regulation of the prostaglandin cascade is believed to play a significant role in carcinogenesis [29]. The data presented in this study demonstrate that KSHV vGPCR-induces COX-2 mRNA and protein expression in primary vein endothelial cells, yet has no effect on COX-1 expression. We further showed in transient expression assays, vGPCR activates COX-2 promoter-directed gene expression. The vGPCR-induced COX-2 expression results in a 20-fold increase in PGE2 that is significantly reduced.
in the presence of a COX-2 specific inhibitor. These results demonstrate a mechanism by which a lytic phase protein, vGPCR, encoded by KSHV may exert paracrine effects through COX-2 dependent prostaglandin induction.

Over-expression of COX-2 has emerged as a prominent feature of virtually every form of cancer [29]. The role of COX-2 as a critical mediator of cancer progression is supported by numerous studies showing that the induction of constitutive COX-2 expression and the resulting biosynthesis of PGE$_2$ are sufficient to stimulate all of the key features of carcinogenesis including mutagenesis, mitogenesis, angiogenesis, metastasis, inhibition of apoptosis and immunosuppression [29]. KS lesions are characterized by increased levels of PGE$_2$ and cyclic AMP phosphodiesterase compared to those within the surrounding tissues [16] suggesting that induction of COX-2 may be an important mediator of KS. Importantly, Sharma-Walia et al recently demonstrated that infection with KSHV induces robust COX-2, but not COX-1, expression in HMVEC and HFF and increased their secretion of PGE$_2$ [17]. They further showed that although viral binding and entry induced moderate levels of COX-2, viral gene expression significantly increased COX-2 induction. To date, no specific KSHV gene products have been associated with the observed COX-2 increase. Our studies provide evidence that KSHV vGPCR induces COX-2 expression in primary vascular endothelial cells and may be responsible for the COX-2 and PGE$_2$ increases observed following infection in microvascular endothelial cells and in KS clinical specimens, respectively.

Emerging evidence points to vGPCR expression as essential for KS development. It is the only KSHV gene that when expressed in the vascular endothelium of mice is able to produce vascular tumors [30] and transgenic mice that express vGPCR under either a ubiquitous (SV40) promoter or a T cell-specific (CD2) promoter also develop dermal angioproliferative lesions that closely resemble those seen in KS [31,32]. Moreover, siRNA-mediated suppression of vGPCR in mice expressing the entire KSHV genome was sufficient to block VEGF secretion and tumorigenesis, leading to significant retardation in tumor growth [33]. Whether induction of COX-2 leads to the angiogenic and tumorigenic effects of vGPCR is currently under investigation.

Increased expression of PGE$_2$ due to vGPCR expression may have a role in KSHV replication as well. The study by Sharma-Walia et al suggests that COX-2 and PGE$_2$ play roles in facilitating latent viral gene expression and the establishment and maintenance of latency [17]. This data
together with results presented here could explain how vGPCR, a lytic gene normally expressed only in cells destined for lysis, might induce a tumor. Even though only a small percentage of KS cells express vGPCR within KS lesions, vGPCR induced COX-2 expression and consequent PGE₂ secretion could initiate tumorigenesis and promote viral latency through paracrine mechanisms. There are no published reports describing a clinical link between COX-2 and KS, however, we feel that this hypothesis warrants further investigation.

COX inhibitors such as aspirin inhibit COX activity by blocking the conversion of arachidonic acid to PGH₂ by competing with free arachidonic acid for the cyclooxygenase active sites. The COX-1 and COX-2 pharmacological inhibitors NS-398, SC-560, and Indomethacin used in this study abrogate cyclooxygenase activity by a similar mechanism. The use of COX-2 inhibitors would provide a viable therapeutic strategy to abrogate PGE₂ secretion since prostaglandin E synthase (PGES) cannot synthesize PGE₂ without PGH₂ and there are no direct inhibitors of PGES currently available. Given the correlation of COX-2 in other cancer models, and evidence that regular intake of a COX-2 inhibitor reduces cancer risk [29], future investigations into the mechanisms of KSHV induced COX-2 expression and prostaglandin activity may lead to new treatments for KS patients.

Methods

Reagents

NS-398 was purchased from Cayman Chemical, Ann Arbor, MI and sodium butyrate (NaB) was purchased from Sigma, St. Louis, MO.

Cell culture

Pooled HUVEC (Cambrex BioScience, Walkersville, MD) were cultured on 0.2% gelatin coated plates in medium 199 (M-199) (Invitrogen, Carlsbad, CA) supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine, 2 mM penicillin-streptomycin, and 1% endothelial cell growth supplement (ECGS) (BD Biosciences, Bedford, MA). Phoenix GP retroviral packaging cells (ATCC, Manassas, VA) were grown in Dulbecco’s modified essential medium (DMEM, Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine, and 2 mM penicillin-streptomycin. HeLa cells (ATCC) were grown in minimal essential media supplemented with 10% FBS, 2 mM L-glutamine, 2 mM penicillin-streptomycin, non-essential amino acids, and sodium pyruvate. All cells were grown at 37°C with 5% CO₂.

Plasmids

To construct vGPCR-expressing plasmids, KSHV vGPCR cDNA was cut from MIGR-ORF74 (generous gift from Marvin Reitz, Institute of Human Virology, Baltimore, MD) by BglIII and EcoRI digestion [12]. The digested vGPCR fragment was separated by gel electrophoresis, purified using QIAquick PCR Purification Kit (Qiagen,
Valencia, CA) and ligated into either BamHI and EcoRI digested pBABE-green fluorescent protein (GFP) retroviral plasmid (generous gift from Andrew Rice, Baylor University, Houston, TX) [34] or BamHI and EcoRI digested pcDNA3 (Invitrogen) using T4 DNA Ligase (Invitrogen). pBABE-GFP and pBABE-GFP-vGPCR were propagated in Escherichia coli strain DH15a (Invitrogen). All plasmids were harvested using QIAfilter Plasmid Maxi Kit (Qiagen) according to the manufacturer's instructions and quantified by spectrophotometry.

Retrovirus Production and Infection
BABE(VSV-G) pseudotypes were produced by transfecting Phoenix GP cells with an equal amount of either pBABE-GFP or pBABE-GFP-vGPCR and pVSV-G using calcium phosphate precipitation as previously described [35]. The medium was removed from each culture at 15 hours post-transfection, cells were washed twice with phosphate-buffered saline (PBS), and DMEM supplemented with 5 mM NaB was added. Fourteen hours later, the cells were washed twice with PBS and the medium was changed to M-199 supplemented with 10% FBS. At 48 hours post-transfection, the virus-containing medium was collected, centrifuged at 200 x g for 10 minutes to remove debris, passed through a 0.45-μm filter, aliquoted and stored at -80°C. Virus titers were quantified by GFP expression in retrovirus-transduced NIH3T3 cells (ATCC) using fluorescent microscopy. HUVEC between passages 4 and 6 were plated 24 hour prior to infection at a confluence of 40%. At the time of infection, the medium was replaced with BABE or BABE-vGPCR retrovirus-containing medium diluted in M-199 (20% FBS) with ECGS to an MOI of 0.5. The virus-containing medium was removed 24 hour post-infection and fresh M-199 (20% FBS) with ECGS was added every 24 hours for the remainder of each experiment.

Western Blot Analysis
Whole cell extracts were harvested in RIPA Buffer (50 mM Tris-HCl pH 7.5, 1% Nonidet P-40, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonylfluoride, 1 mM sodium orthovanadate, 1 mM sodium fluoride, and 10 μg/ml aprotinin), rotated for 30 min at 4°C, and centrifuged at 14,000 rpm for 15 min. Clarified protein was quantified by Bradford assay (Sigma). 45 μg of protein from each sample was separated by SDS-PAGE, transferred to a PVDF membrane, and incubated overnight with COX-1 or COX-2 monoclonal antibody (Cayman Chemicals, Ann Arbor, MI) diluted 1:1000 in 5% non-fat milk/0.1% Tween-TBS. After incubation with an anti-mouse secondary antibody conjugated with horseradish peroxidase (1:5000 dilution, Sigma), the immunocomplexes were visualized by enhanced chemiluminescence (Amersham Biosciences, Buckinghamshire, England). β-actin expression was measured as a loading control using an anti-β-actin rabbit polyclonal antibody (1:1000) (Sigma) and detected by a
1:5000 dilution of horseradish peroxidase conjugated donkey anti-rabbit antibody (Amersham Biosciences).

**PGE2 Quantification**

Conditioned medium from BABE and BABE-vGPCR transduced HUVEC was centrifuged at 14,000 rpm for 15 min at 4°C and supernatants assayed immediately using a monoclonal PGE2 EIA kit (Cayman, Ann Arbor, MI) according to the manufacturer's protocol.

**Luciferase Assay**

HeLa cells were co-transfected in duplicate with 5 μg of full-length COX-2 promoter luciferase plasmid and increasing amounts of either pcDNA3 or pcDNA3-vGPCR using calcium phosphate precipitation as previously described [35]. Medium was removed 18 hours post-transfection and replaced with fresh culture medium. At 48 hours post-transfection, medium from each well was replaced with Luciferase Lysis Buffer (Promega, Madison, WI) and incubated at -80°C for 10 min. Each sample was thawed to room temperature, scraped, and centrifuged at 14,000 rpm for 15 min at 4°C. Clarified protein for each sample was quantified by Bradford assay (Sigma) according to the manufacturer's protocol. Luciferase Reporter Buffer (Promega) was added to each sample and relative luciferase activity was measured in triplicate using a lumino-meter (Lumat LB9507, Berthold).

**Real-Time Reverse Transcriptase PCR**

Total cellular RNA was isolated using RNeasy Total RNA Kit (Qiagen) according to the manufacturer's instructions. DNA was eliminated from all samples using Turbo-DNase I (Ambion, Austin, TX). The RNA from each sample was quantified by spectrophotometry. RNA (250 ng) from each sample was converted to cDNA using iScript Reverse Transcriptase (RT) (Bio-Rad, Hercules, CA) following the manufacturer's protocol. Two microliters of cDNA was amplified in 20 μl reactions containing primers at 250 nM in iQ SYBR Green Supermix (Bio-Rad). PCR was performed for 40 cycles consisting of 95°C for 15 sec and 60°C for 60 sec using an iCycler iQ Real Time Detection System (Bio-Rad) using primers specific for COX-2 mRNA [36] and human riboprotein 36B4 [37]. Dilution curves showed that PCR efficiency was 96–100% for all primer sets used. All samples were run in triplicate on the same plate for each primer set. Negative controls, such as cDNA reactions without reverse transcriptase or RNA, and PCR mixtures lacking cDNA were included in each PCR to detect possible contaminants. Following amplification, specificity of the reaction was confirmed by melt curve analysis. Relative quantitation was determined using the comparative C(T) method with data normalized to 36B4 mRNA and calibrated to the average ΔC(T) of untreated controls.

**Statistical analysis**

Data are presented as the means +/- standard error of the means (SEM). Data from vGPCR-expressing groups were compared to control groups and significant differences were determined by one-way analysis of variance (ANOVA) followed by Tukey's post hoc t-test (GraphPad Prism Home, San Diego, CA).

**Figure 5**

vGPCR induced PGE2 secretion is dependent on COX-2. A) HUVEC were infected with BABE or BABE-vGPCR at time 0 and analyzed at the indicated time points for the amount of PGE2 in conditioned medium using an EIA kit. The vGPCR-expressing HUVEC conditioned media demonstrates a time-dependent increase in PGE2 secretion (* = p < 0.001). Graph and SEM is representative of three independent experiments. B) At 24 hours post-infection, BABE-vGPCR infected HUVEC were treated with the non-selective COX inhibitor indomethacin (Indo), the selective COX-2 inhibitor (NS-398), or the selective COX-1 inhibitor SC-560 and PGE2 in the conditioned media was quantified at 48 hours post-infection by EIA. PGE2 secretion is reduced in a dose-dependent manner in Indo and NS-398 treated BABE-vGPCR infected HUVEC. The COX-1 selective inhibitor SC-560 had a minimal effect on PGE2 secreted from vGPCR expressing HUVEC. Graph indicates fold induction in PGE2 secretion over BABE-HUVEC and is representative of three independent experiments.
Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
BDS participated in experimental design, implementation, interpretation of results and drafting the manuscript. HLL helped with real-time PCR analyses. HEM helped with retroviral production. ABN performed western blot analyses. JAL participated in experimental design. GS and LM provided expertise in real-time PCR analyses. MKO participated in experimental design and data interpretation and manuscript preparation. DES participated in experimental design, data interpretation and manuscript preparation. All authors read and approved the final manuscript.

Acknowledgements
We thank Marvin Reitz, University of Maryland-Baltimore for the MIGR and MIGR-ORF retroviral plasmids, Andy Rice, Baylor University for the BABE retroviral plasmid, Gary Nolan, Stanford University for the VSV-G plasmid, and Nicholas Bazan, Louisiana State University for the full-length COX-2 promoter luciferase plasmid. We also thank MaryBeth Ferris for excellent technical assistance in confirmation of specific experiments. This study was supported in part by NIH/NICHD045786 (CAM), NIH/NHLBI HL083480 (JAL) and a grant from the Louisiana Cancer Research Consortium (DES).

References
1. Antonan K, Chang Y: Kaposi’s sarcoma. N Engl J Med 2000, 342(14):1027-1038.
2. Chang Y, Cesaran E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994, 266(5192):1865-1869.
3. Cesaran E, Chang Y, Moore PS, Said JW, Knowles DM: Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995, 332(18):1186-1191.
4. Solarju J, Grolliet L, Oksendal E, Caciob P, Cazals-Hatem D, Babint P, D’Agay MF, Clavijp J, Raphael M, Degos L, Sigaux F: Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995, 86(4):1276-1280.
5. Ganesan D: Kaposi’s Sarcoma-Associated Herpesvirus. In Fields Virolology Volume 2. Fifth edition. Edited by: Knipe DM, Howley PM. Philadelphia, Lippincott Williams and Wilkins; 2007:2847-2888.
6. Zhong W, Wang H, Herndier B, Ganesan D: Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A 1996, 93(13):6461-6466.
7. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganesan D: Haase AT: Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997, 71(1):715-719.
8. Bais C, Santomass B, Coso O, Arvanitakis L, Raaka EG, Guskind JS, Asch AS, Cesaran E, Gershgorn MC, Mersi EA: G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus. A viral oncogene and angiogenesis activator. Nature 1998, 391(6662):86-89.
9. Guo HC, Browning P, Nicholas J, Hayward GS, Tschachler E, Jiang YW, Sadowska M, Raffeld M, Colombini S, Gallo RC, Reitz MS Jr: Characterization of a chemokine receptor-related gene in human herpesvirus 8 and its expression in Kaposi’s sarcoma. Virology 1997, 228(2):371-378.
10. Arvanitakis L, Geras-Raaka E, Varm A, Gershgorn MC, Cesaran E: Human herpesvirus KHSV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997, 385(6614):347-350.
11. Cannon M, Philpot NJ, Cesaran E: The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol 2003, 77(1):57-67.
12. Pati S, Cavois M, Guo HG, Foulle JS Jr., Kim J, Feldman RA, Reitz M: Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi’s sarcoma pathogenesis. J Virol 2001, 75(18):8660-8673.
13. Pati S, Foulle JS, Barabitskaya O, Kim J, Nair BC, Hone D, Smart J, Feldman RA, Reitz M: Human herpesvirus 8-encoded vGPCR activates nuclear factor of activated T cells and collaborates with human immunodeficiency virus type 1 Tat. J Virol 2003, 77(10):5759-5773.
14. Smitt M, Verzijl D, Casarosa P, Navis M, Timmerman H, Leurs R: Kaposi’s Sarcoma-Associated Herpesvirus-Encoded G Protein-Coupled Receptor Activates the G Protein p44/p42 MAPK and Akt via Gi and Phospholipase C-Dependent Signaling Pathways. J Virol 2002, 76(4):1744-1752.
15. Sodhi A, Montaner S, Patel V, Bais C, Zohar M, Mersi EA, Guskind JS: The Kaposi’s sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000, 60(17):4873-4880.
16. Ambrus J, Stolil H, Klein EA, Karakousis CP, Stadler S: Increased Prostaglandin E2 and cAMP Phosphodiesterase levels in Kaposi’s Sarcoma - A virus against host defense. Res Commun Chem Pathol Pharmacol 1992, 78(2):249-252.
17. Sharma-Walia N, Raghu H, Sadasogan S, Sivakumar V, Veettil MV, Naranatt PP, Smith PM, Chandran B: Cyclooxygenase 2 induced by Kaposi’s sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol 2006, 80(13):6534-6552.
18. Naranatt PP, Krishnan HH, Svojanovsky SR, Bloomer C, Mathur S, Chandran B: Hose gene induction and transcriptional reprogramming in Kaposi’s Sarcoma-Associated Herpesvirus (KSHV/HHV-8)-infected endothelia, fibroblasts, and B cells: Insights into modulation events early during infection. Cancer Res 2004, 64(1):72-84.
19. Bais C, Balhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
20. Fosslien E: Molecular Pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000, 30:3-21.
21. Dubois RN, Abramson SB, Czufford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998, 12:1063-1073.
22. Akarsarayenont P, Chotewuttakorn S, Tekachaisak K, Thaworn A: The effects of COX-metallobes on cyclooxygenase-2 induction in LPS-treated endothelial cells. J Med Assoc Thai 2001, 84 Suppl 1:356:69-709.
23. Akarsarayenont P, Tekachaisak K, Chotewuttakorn S, Thaworn A: The induction of cyclooxygenase-2 in IL-1beta-treated endothelial cells is inhibited by prostaglandin E2 through cAMP. Mediators Inflamm 1999, 6(6):287-294.
24. Smith WL, Devitt DL, Garavito RM: Cyclooxygenase Activates p44/p42 MAPK and Akt via Gi and phospholipase C-dependent signaling pathways. J Virol 1997, 71(1):715-719.
25. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, Nguyen B, Tsing S, Bach C, Freire J: Purification, characterization, and selective inhibition of the human herpesvirus 8 G protein-coupled receptor. A viral oncogene and angiogenesis activator. Nature 1998, 391(6662):86-89.
26. Bais C, Van Geelen A, Jevic P, Azizian C, Dias S, Silverstein RL, Raffel S, Mersi EA: Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 2003, 3(2):131-143.
27. Barnett J, Chow J, Ives D, Chiu M, Mackenzie R, Osen E, Nguyen B, Tsing S, Bach C, Freire J: Purification, characterization, and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994, 1209(1):130-139.
28. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J 1995, 305( Pt 2):479-484.
29. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert I, Isakson PC: Pharmacological anal...
ysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 1998, 95:13313-13318.

29. Harris RE. Cyclooxygenase-2 (COX-2) and the Inflammogenesis of Cancer. In Inflammation in the Pathogenesis of Chronic Diseases Volume 42. Edited by: Harris RE. Netherlands, Springer; 2007:93-126.

30. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003, 3(January 2003):23-36.

31. Guo HG, Sadowska M, Reid W, Tschachler E, Hayward G, Reitz M. Kaposi's Sarcoma-Like Tumors in a Human Herpesvirus 8 ORF74 Transgenic Mouse. J Virol 2003, 77(4):2631-2639.

32. Yang TY, Chen SC, Leach MW, Manfra D, Honeey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, Chensue SW, Lira SA. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000, 191(3):445-454.

33. Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM, Asgari Z, Hooper AT, La Perle KM, Hilsher C, Gao SJ, Dittmer DP, Rafii S, Mesri EA. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 2007, 11(3):245-258.

34. Foskett SM, Ghose R, Tang DN, Lewis DE, Rice AP. Antiapoptotic function of CdK9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol 2001, 75(3):1220-1228.

35. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning A Laboratory Manual. Volume 3. 2nd edition. Plainview, Cold Spring Harbor Laboratory Press; 1989.

36. Sun K, Ma R, Cui X, Campos B, Webster R, Brockman D, Myatt L. Glucocorticoids induce cytosolic phospholipase A2 and prostaglandin H synthase type 2 but not microsomal prostaglandin E synthase (PGES) and cytosolic PGES expression in cultured primary human amnion cells. J Clin Endocrinol Metab 2003, 88(11):5564-5571.

37. Simpson DA, Feehey S, Boyle C, Stitt AW. Retinal VEGF mRNA measured by SYBR green I fluorescence: A versatile approach to quantitative PCR. Mol Vis 2000, 6:178-183.